In This Article:
-
Revenue (Q4 FY25): INR603 crore, up 10.5% from INR545 crore in Q4 FY24.
-
Revenue (Full Year FY25): INR2,461 crore, up 10.5% from INR2,227 crore in FY24.
-
Revenue per Patient (Q4 FY25): INR887, up 6.4% from INR833 in Q4 FY24.
-
Test per Patient (Q4 FY25): 3.07, compared to 2.91 in Q4 FY24.
-
EBITDA (Q4 FY25): INR169 crore, up 16.9% with a margin of 28.1%.
-
EBITDA (Full Year FY25): INR696 crore, up 14.2% with a margin of 28.3%.
-
PBT (Q4 FY25): INR154 crore, up 28.1% with a margin of 25.5%.
-
PBT (Full Year FY25): INR625 crore, up 23.6% with a margin of 25.4%.
-
PAT (Q4 FY25): INR156 crore, up 81.4% with a margin of 25.8%.
-
PAT (Full Year FY25): INR492 crore, up 35.9% with a margin of 20%.
-
EPS (Q4 FY25): INR18.6, compared to INR10.1 in Q4 FY24.
-
EPS (Full Year FY25): INR58.5, up 35.9% from INR43 in FY24.
-
Net Cash and Equivalents (March 31, 2025): INR1,229 crore.
-
Final Dividend: 60% or INR6 per share, total dividend for the year 40% or INR24 per share.
-
Sample Volumes (Q4 FY25): 20.9 million, up 9.5%.
-
Patient Volumes (Q4 FY25): 6.8 million, up 3.8%.
-
New Labs Added (FY25): 18 new labs.
Release Date: April 25, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Dr. Lal PathLabs Ltd (BOM:539524) reported a revenue growth of 10.5% for Q4 FY25, reaching INR603 crore, compared to INR545 crore in the same quarter last year.
-
The company achieved a significant increase in PAT for Q4 FY25, which came in at INR156 crore, reflecting a growth of 81.4% compared to the previous year.
-
Sample volumes grew by 9.5% to 20.9 million, while patient volumes increased by 3.8% to 6.8 million, indicating strong operational performance.
-
The company added 18 new labs during the year, expanding its presence in Tier 3 and Tier 4 markets, which is expected to drive future growth.
-
Dr. Lal PathLabs Ltd (BOM:539524) successfully implemented Microsoft D365 and other IT systems, creating a unified digital infrastructure across its brands, enhancing operational efficiency.
Negative Points
-
Despite the revenue growth, the company anticipates a potential decrease in EBITDA margins to around 27% in FY26 due to investments in new geographies and digital initiatives.
-
The West region's revenue contribution decreased slightly, raising concerns about growth in that area, particularly with the integration of Suburban Diagnostics.
-
The company faces intense competition from both organized and unorganized players, including new entrants like pharma companies entering the diagnostics sector.
-
There is a strategic decision not to increase prices, which could impact revenue growth if cost pressures increase.
-
The company has a relatively low revenue contribution from radiology, less than 5%, which may limit diversification and growth opportunities in that segment.